GSK’s first lung cancer approval, a new IPO path and more
This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma. The episode c...
24 Jul 11min
Why modern clinical trials need a finance-first strategy (Sponsored)
Clinical trial success depends on more than scientific rigor and operational execution. It also depends on the financial systems that support every stage of a study. In this episode of The Top Line, Z...
20 Jul 17min
5 emerging biotech hubs
Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead? In ...
17 Jul 24min
Operating at the speed of science: The new medical affairs playbook (Sponsored)
Medical affairs is at an inflection point. As science advances and healthcare professionals gain access to information in real time, medical teams face a mandate to deliver insight with greater speed,...
14 Jul 22min
Decision readiness is the next AI advantage (Sponsored)
AI is reshaping how organizations compete, but more data and more tools do not automatically lead to better decisions. In this episode of The Top Line, Justin Masterson, senior vice president of human...
13 Jul 18min
A $10B deal, China trial scrutiny and highlights from ADA 2026
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. First, we discuss Vertex’s $10...
10 Jul 24min
The deal before the deal
Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple. In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a disc...
26 Jun 41min
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how FDA Breakthrough Therapy and RMAT designati...
22 Jun 20min
